Skip to content

The Randomized Double-blind Controlled Clinical Trial of Combination of Intravitreal Ranibizumab With or Without Macular Laser Photocoagulation for Macular Edema Secondary to Branch Retinal Vein Occlusion

The Randomized Double-blind Controlled Clinical Trial of Combination of Intravitreal Ranibizumab With or Without Macular Laser Photocoagulation for Macular Edema Secondary to Branch Retinal Vein Occlusion

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-17010568
Enrollment
Unknown
Registered
2017-02-07
Start date
2017-02-06
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Branch retinal vein occlusion

Interventions

1:macular laser
2:no

Sponsors

Beijing Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Written informed consent 2. Male or female Chinese patients = 18 years of age with BRVO and 3. Visual impairment due to ME secondary to BRVO in at least one eye with BCVA score between 73 and 24 and at least 24 letters in the other eye.

Exclusion criteria

Exclusion criteria: 1. Unable to finish the follow-up visits; 2. Pregnant or nursing (lactating) women or women of child-bearing; 3. potential without using effective contraception; 4. Stroke or myocardial infarction less than 3 months prior to screening visit; 5. Renal failure OR creatinine levels > 2.0 mg/dl; 6. Uncontrolled hypertension; 7. Active ocular infection or intraocular inflammation in any eye; 8. Neovascularization of the iris or neovascular glaucoma in any eye; 9. History of uveitis or vitreomacular traction in any eye; 10. Treatment with any anti-angiogenic drugs within 3 months prior to baseline visit in any eye; 11. Glaucoma or IOP = 24 mmHg in study eye; 12. Active proliferative diabetic retinopathy in study eye; 13. Use of other investigational drugs within 30 days and systemic anti-VEGF drugs within 6 months prior to baseline visit; 14. Prior laser photocoagulation or intraocular procedure within 3 months; 15. prior to baseline in study eye; 16. History of intravitreal corticosteroid treatment in phakic study eye, and in aphakic or pseudophakic within 3 months prior to screening; 17. History of vitrectomy in study eye; 18. Other protocol defined inclusion /exclusion criteria may apply.

Design outcomes

Primary

MeasureTime frame
best corrected visual acuity;

Secondary

MeasureTime frame
injections;

Countries

China

Contacts

Public ContactYu Xiao-bing

Beijing Hospital

yuxiaobing@sina.com+86 010-85132171

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026